Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream

Reuters

2025/07/22

Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream

Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize $(ABC.AU)$ strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553709253"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553709253\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553709253?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553709253","market":"fut","top_or_hot":-1,"title":"Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by <a href=\"https://laohu8.com/S/WSCO\">Wall Street</a> Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize <a href=\"https://laohu8.com/S/ABC.AU\">$(ABC.AU)$</a> strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-22 20:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by <a href=\"https://laohu8.com/S/WSCO\">Wall Street</a> Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize <a href=\"https://laohu8.com/S/ABC.AU\">$(ABC.AU)$</a> strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL1Bh3Sd:1","article_id":"2553709253","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553709253","pubTimestamp":1753186525,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aditxt, Inc.  recently highlighted the innovations of its wholly owned subsidiary, Adimune, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize  strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ADTX":"ADiTx Therapeutics"},"translate_title":"阿迪穆尼™占据中心舞台：Aditxt子公司在即将到来的直播中瞄准自身免疫性突破","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADTX":0.9},"content_text":"Adimune™ Takes Center Stage: Aditxt Subsidiary Targets Autoimmune Breakthroughs at Upcoming Livestream\n    \n\n        Aditxt, Inc. (Nasdaq: ADTX) recently highlighted the innovations of its wholly owned subsidiary, Adimune™, Inc., which is spearheading efforts to develop therapeutics targeting autoimmune diseases. During a livestream hosted by Wall Street Reporter, CEO Amro Albanna discussed Adimune's pioneering approach to modulating the immune system, aiming to retrain it to prevent autoimmune diseases rather than merely treating symptoms. The session outlined key advancements, including planned first-in-human clinical trials and target indications such as Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome. Albanna emphasized Adimune's potential to transform treatment paradigms and its alignment with Aditxt's broader Acquire, Build, Capitalize $(ABC.AU)$ strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722372414) on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}